Company: RNAC
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001453687-25-000075
Chunk: 82

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 82
---
 each January 1, until and including January 1, 2026, by an amount equal to the lesser of: (a) 1% of the number of shares of the Company’s Common Stock outstanding on the last day of the applicable preceding calendar year and (b) such smaller number of shares as is determined by our Board, subject to an aggregate limit of 63,460 shares of Common Stock that may be issued under the 2016 ESPP.

(3) Includes the 2016 Plan and the 2016 ESPP.

(4) Includes outstanding options to purchase 581,700 shares of Common Stock and 330,719 outstanding RSUs to purchase shares of Common Stock under the 2016 Plan.

(5) As of December 31, 2024, the weighted-average exercise price of outstanding options under the 2016 Plan was $19.66.

(6) Represents 3,520,174 shares available for issuance under the 2016 Plan and 45,795 shares available for issuance under the 2016 ESPP (of which 0 shares were issued with respect to the purchase period in effect as of December 31, 2024, which purchase period ended on February 29, 2024).

(7) Includes the 2018 Plan and the Old Cartesian Plan. See Note 13 to our consolidated financial statements included in our 2024 Annual Report for a description of the material features of the 2018 Plan and the Old Cartesian Plan.

(8) Includes outstanding options to purchase 348,083 shares of Common Stock under the 2018 Plan and outstanding options to purchase 776,252 shares of Common Stock and 113,519 outstanding RSUs to purchase shares of Common Stock under the Old Cartesian Plan.

(9) As of December 31, 2024, the weighted-average exercise price of outstanding options under the 2018 Plan was $19.56 and the weighted-average exercise price of outstanding options under the Old Cartesian Plan was $2.86.

(10) Represents 611,960 shares available for issuance under the 2018 Plan and 27,270 shares available for issuance under the Old Cartesian Plan.

#### Option Grant Practices
We do not have any program, plan, or obligation that requires us to grant equity awards on specified dates, though the Company’s long-standing practice has been for the Compensation Committee to meet each December to discuss recommendations to the Board on executive compensation adjustments for the next fiscal year. As part of this